Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

• Main Authors: Lyn Guenther (Author), Alison Potts Bleakman (Author), Jamie Weisman (Author), Yves Poulin (Author), Lynda Spelman (Author), Russel Burge (Author), Janelle Erickson (Author), Kristin Todd (Author), Clinton C. Bertram (Author), Caitriona Ryan (Author)
• Format: Book
• Published: Medical Journals Sweden, 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Ixekizumab was efficacious in treating moderate-to-severe genital psoriasis over 12 weeks. We evaluated the long-term efficacy and safety of ixekizumab for up to 52 weeks. Patients were randomized to 80 mg ixekizumab every 2 weeks or to placebo through Week 12, then received 80 mg open-label ixekizu...